H.R. 5237 — Reduced Costs and Continued Cures Act of 2021

Summary

Reduced Costs and Continued Cures Act of 2021

This bill establishes and alters several programs and requirements relating to the prices of prescription drugs.

For example, the bill establishes and alters several requirements under Medicare and Medicaid, including

requiring drug manufacturers to issue rebates to the Centers for Medicare & Medicaid Services for covered drugs under Medicare that cost $100 or more and for which the average manufacturer price increases faster than inflation,
capping annual out-of-pocket spending under the Medicare prescription drug benefit, and
increasing the maximum rebate amount under the Medicaid Drug Rebate Program.

The bill also makes changes relating to market exclusivities and manufacturer price concessions for prescription drugs, including

authorizing the Federal Trade Commission to initiate proceedings against parties to settlements of patent infringement claims that have anticompetitive effects with respect to drugs or biologics,
limiting in certain instances the number of patents that the manufacturer of a biologic can assert in a lawsuit against a company seeking to sell a biosimilar version, and
nullifying regulations relating to the treatment of certain Medicare prescription drug benefit rebates from drug manufacturers for purposes of federal anti-kickback laws.

H.R. 2706Freedom from Price Gouging Act
2021-04-21Referred to the Subcommittee on Health.
Related
H.R. 2855Star Rating for Biosimilars Act
2021-04-27Referred to the Subcommittee on Health.
Related
H.R. 2873Affordable Prescriptions for Patients Through Promoting Competition Act of 2021
2021-09-29Ordered to be Reported in the Nature of a Substitute by the Yeas and Nays: 27 - 16.
Related
H.R. 2884Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act
2021-09-30Ordered to be Reported in the Nature of a Substitute by Voice Vote.
Related

2021-09-10
Introduced in House
2021-09-10
Introduced in House
2021-09-10
Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
2021-09-10
Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
2021-09-10
Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
2021-09-10
Referred to the Subcommittee on Health.
2021-09-13
Referred to the Subcommittee on Health.
2022-11-01
Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.
2022-11-01
Referred to the Subcommittee on Courts, Intellectual Property, and the Internet.